Pfanstiehl Announces New Histidine Products for Biopharmaceutical Formulations

July 14, 2020

Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications.

Pfanstiehl announced that it has launched high purity, low endotoxin, low metal L-histidine and L-histidine hydrochloride monohydrate for a new quality standard for amino acids.

Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications, a June 25, 2020 company press release said. The products are now available for customer qualification and manufacturing, product profiles, and regulatory documentation.

“Pfanstiehl’s amino acid specifications exceed regulatory requirements and reflect our leadership in setting high quality industry standards for the biopharma market,” said Chandra Kelley, director of business development, Pfanstiehl, in the press release.

Source: Pfanstiehl